Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UBX1325 50 μL · 1 trial · 1 indication
Ocular and systemic safety and tolerability of a repeat IVT injection of UBX1325 compared to active-control (aflibercept) evaluated by treatment emergent adverse events (TEAEs) through Week 24
| Arm | Type | Description |
|---|---|---|
| UBX1325 | EXPERIMENTAL | - |
| Aflibercept (EYLEA ®) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| UBX1325 injection 50 μL | DRUG | Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | DRUG | Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28. |
Inclusion Criteria: * Patients aged ≥50 years. * Active CNV associated with age-related macular degeneration as evidenced on FA and SD-OCT with presence of intraretinal or subretinal fluid at Screening and Day 1 * BCVA in the study eye (most affected) of 70 to 20 ETDRS letters (equivalent to 20/40 ...
UBX1325 is an investigational small molecule being developed for the treatment of neovascular age-related macular degeneration, a condition that causes abnormal blood vessel growth and vision loss. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
UBX1325 is being developed by Unity Biotechnology, Inc., a company traded on the stock exchange under the ticker symbol UBX. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy for neovascular age-related macular degeneration.
UBX1325 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. A Phase 2 clinical trial has been completed to evaluate its safety, tolerability, and efficacy in patients with neovascular age-related macular degeneration.
UBX1325 has been studied in one completed Phase 2 clinical trial with the identifier NCT05275205, known as the ENVISION study. This trial enrolled 51 participants in the United States and evaluated the drug in patients with neovascular age-related macular degeneration.
UBX1325 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being studied specifically for neovascular age-related macular degeneration and is not known to be marketed under any other brand name.